NCT00491530 - A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia | Biotech Hunter

Enrollment

310

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Mixed Dyslipidemia

Interventions

DRUG

ABT-335

Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study

DRUG

rosuvastatin calcium

Oral coadministration of rosuvastatin calcium (20 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study

DRUG

simvastatin

Oral coadministration of simvastatin (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study

DRUG

atorvastatin calcium

Oral coadministration of atorvastatin calcium (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study

Trial Locations (1)

60064

Medical Information Specialist, Abbott Park